L3VLUP
ProSign in

MAZE · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MAZEGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MAZE
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterMAZEGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 2021none listed holders, n.a.24 holders, $14.5bn
Q2 2021none listed holders, n.a.18 holders, $14.9bn
Q3 2021none listed holders, n.a.20 holders, $16.4bn
Q4 2021none listed holders, n.a.20 holders, $16.8bn
Q1 2022none listed holders, n.a.28 holders, $13.2bn
Q2 2022none listed holders, n.a.26 holders, $13.6bn
Q3 2022none listed holders, n.a.24 holders, $13.3bn
Q4 2022none listed holders, n.a.32 holders, $21.1bn
Q1 2023none listed holders, n.a.27 holders, $21.8bn
Q2 2023none listed holders, n.a.24 holders, $20.7bn
Q3 2023none listed holders, n.a.24 holders, $20.0bn
Q4 2023none listed holders, n.a.22 holders, $21.5bn
Q1 2024none listed holders, n.a.30 holders, $20.3bn
Q2 2024none listed holders, n.a.28 holders, $18.5bn
Q3 2024none listed holders, n.a.29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 20252 holders, $10m33 holders, $32.0bn
Q2 20251 holders, $12m27 holders, $30.9bn
Q3 20251 holders, $27m23 holders, $29.4bn
Q4 20254 holders, $213m25 holders, $34.3bn
Q1 20265 holders, $127m25 holders, $38.5bn
Q2 20265 holders, $170m26 holders, $34.2bn
MAZE

Maze Therapeutics Inc

Holders
4
Reported value
$213m
Buyers
15
Sellers
8

Breadth +7 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
25
Reported value
$34.3bn
Buyers
18
Sellers
19

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MAZE (1)

Freestone Grove Partners LP

Only GILD (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →